Latest news with #transplantation
Fast Company
6 days ago
- Health
- Fast Company
Can healthcare go green without compromising safety?
U.S. hospitals generate nearly six million tons of waste each year, and a single patient can be responsible for more than 30 pounds a day. Much of that waste comes from the operating room (OR), which accounts for up to a third of a hospital's total output and is among the most expensive areas to manage. A large portion comes from single-use devices, packaging, and transport materials. These practices are often criticized, and not without reason. But in settings like transplantation, much of that waste is directly tied to protecting patients. I'm often asked, 'Why not make devices reusable?' or 'What about the environmental impact?' After years in the OR and working alongside transplant teams, I've asked those same questions. The answers aren't black and white, but that doesn't mean we should stop asking. Sustainability often gets reduced to packaging claims or material swaps. But the real impact lies in the systems we build around the product. That's the conversation we need to be having. Why single-use still matters Some of the industry's most criticized practices, like single-use devices, are also the least negotiable. Single-use eliminates the need for sterilization between uses, simplifies prep and cleanup, and reduces the risk of infection. The FDA permits reprocessing of certain single-use tools, but only under strict conditions. Nowhere is that margin tighter than in organ transplantation. There are no do-overs when you're handling a human organ. Transplant patients are especially vulnerable to infection due to immunosuppression, and even small lapses in sterility can lead to serious complications. Device-associated infections, from central lines, catheters, and ventilators, are among the most common and serious complications following transplant. The CDC also notes that while concerns persist about reusing single-use devices, more research is needed to define the risks. Devices that reduce infection risk and prevent complications can lead to fewer readmissions, which means fewer hospital resources used and better sustainability over time. The systems around the product Many conversations about sustainability start and stop with the product itself, whether it's recyclable, biodegradable, or made with 'green' materials. But many of the most wasteful decisions happen in how a product moves through the system that supports it. And when that system spans hospitals, suppliers, procurement teams, and legal departments, it's not built for fast change. Even when the intention is there, funding constraints, liability concerns, and the challenge of making changes across large networks often stand in the way. While a fragmented system can't solve the footprint of a single device, medical device companies still have control over how their products are moved and managed, and that's where meaningful change can start. Flying devices around the world might be fast, but it adds unnecessary emissions to an already resource-intensive process. And it's often done not because it's needed, but because it's familiar. Shifting to road transport takes more coordination, but it significantly cuts emissions and gives teams more control over when and how products arrive. What happens after delivery matters just as much. Without a plan for how products are returned, stocked, or moved, operations can shift into reaction mode. That's when waste shows up through emergency shipments, over-ordering, and unused inventory. In kidney transplant, for example, reusable machine perfusion systems have improved outcomes, but broader use has revealed logistical friction, including turnaround delays and higher discard rates. Inefficient habits tend to stay hidden until the consequences catch up. For years, private air travel has been the default in time-sensitive cases, but it comes with a steep environmental cost. At my current company, our team found that one chartered jet can emit as much carbon as manufacturing 200 single-use medical devices. With better planning, commercial flights can often meet the same clinical timelines and reduce emissions without compromising care. Sustainability has to show up in the operational decisions because if the systems around the product are wasteful, it doesn't matter how recyclable the product is. Recyclability won't negate the carbon footprint of wasteful shipping, inefficient production, or reactive inventory habits. A product isn't sustainable if it arrives on a private jet, was rushed through the supply chain, or sits unused on a shelf. Sustainability starts with better questions Healthcare won't eliminate waste entirely. But small changes matter. Reducing reliance on private air travel. Avoiding emergency shipments. Moving production closer to where products are used. None of it sounds radical. But over time, it adds up. And more often than not, it comes down to refusing to accept waste as the cost of doing business. For healthcare leaders, it's worth stepping back to examine the systems tied to a product and where a few deliberate improvements could make an impact. Not every change requires an overhaul. But the right operational shift, at the right point in the process, can reduce waste without ever touching the safety of patient care. And if enough companies commit to that kind of thinking, that's how you move an industry forward.
Medscape
30-05-2025
- Business
- Medscape
What Is Driving Europe's Renal Replacement Therapy Surge?
In 2022, 567,440 patients with end-stage renal disease in Europe received renal replacement therapy (RRT), with an unadjusted prevalence of 1074 per million population. In France, the rate was 1383 per million population among 93,486 patients (mean age, 63.5 years; 62% men). These data were obtained from the European Renal Association Registry, which collects information on RRT in patients with end-stage kidney disease. The RRT data were obtained from 53 registries in 35 countries, covering approximately 530 million individuals. After adjusting for age and sex, France's prevalence was among the highest in Europe (1440 per million population vs 1192 per million population overall). Across the cohort, 56% underwent haemodialysis, 39% had a renal transplant, and 5% received peritoneal dialysis. In 2022, there were 80,389 incident RRT cases in Europe — an unadjusted incidence of 152 per million population, up from 145 per million population in 2021. France reported 163 cases per million people. The age- and sex-adjusted incidence rates were 163 and 168 per million population in Europe and France, respectively. On average, 54% of new cases were aged 65 years or older, and 64% were men. Haemodialysis use increased by 83% with patient age, while peritoneal dialysis and renal transplantation declined by 12% and 5%, respectively. No differences were observed between the sexes. In 2022, 21,261 patients underwent renal transplantation, including 3352 in France. Across Europe, 66% of grafts were from deceased donors compared with 15% in France. Among patients who began RRT between 2013 and 2017, the unadjusted 5-year survival probabilities were 51.5%, 41.3% for those on dialysis, 85.1% for recipients of deceased donor grafts, and 94.2% for recipients of living donor grafts. Dialysis patients aged 20-24 years have an estimated remaining life expectancy of 20 years for men and 21 years for women, which is 39 and 44 years shorter, respectively, than their age-matched peers in the general population. Women account for 24%-46% of RRT cohorts across Europe, from 24% in Iceland to 46% in Estonia, with France at 33%. The initial RRT modality did not differ according to sex. The French National Authority for Health has announced a forthcoming set of best-practice recommendations for live kidney donation, which are expected to be released in the third quarter of 2025. These guidelines aim to enhance both donor and recipient safety, harmonise practices, and improve overall outcomes in live kidney donation procedures, and address recent studies, despite methodological limitations that raised concerns about potential morbidity risks for the recipient.
Yahoo
22-05-2025
- Business
- Yahoo
Transplantation Market Size to Surpass USD 30.5 Billion by 2032, Driven by Rising Organ Failure Cases and Technological Advancements
U.S. Transplantation Market to Grow at 9.64% CAGR, Projected to Reach USD 9.58 Billion by 2032 fueled by Advanced Infrastructure and National Registries. Austin, May 22, 2025 (GLOBE NEWSWIRE) -- Transplantation Market Size & Growth Analysis: According to SNS Insider, The Transplantation Market was estimated at USD 13.76 billion in 2023 and is expected to reach USD 30.50 billion by 2032, at a CAGR of 9.25% during the forecast period of 2024-2032. The transplantation market is experiencing consistent growth owing to increasing rates of organ failure, advancing surgical procedures, and enhanced immunosuppressive regimens. Growing consciousness of organ donation and the increasing healthcare infrastructure further aid the growth of the market. Technological advancements in the form of 3D-printed organs and better preservation techniques are also lending a helping hand in yielding better transplant outcomes, thus making transplantation an integral part of therapy for chronic and life-threatening disorders a Sample Report of Transplantation Market@ U.S. Market Trends The U.S. Transplantation Market was estimated at USD 4.18 billion in 2023 and is expected to reach USD 9.58 billion by 2032, at a CAGR of 9.64% during the forecast period of 2024-2032. The U.S. has the leadership position in the North American transplantation industry, backed by the availability of a well-established healthcare infrastructure, improved organ donation rates, and ongoing technological upgradations in transplantations. The U.S. alone conducted more than 46,000 organ transplants in 2023, a year-over-year increase of 8.7%, according to OPTN. Major Players Analysis Listed in this Report are: AbbVie, Inc. (Zinbryta, Imbruvica) Arthrex, Inc. (AlloSync Pure, Angel System) Zimmer Biomet (Comprehensive Shoulder, Trabecular Metal Technology) Medtronic (Harmony Transcatheter Valve, TYRX Envelope) Novartis AG (Zortress, Simulect) Stryker (Mako Robotic-Arm, Tritanium Implants) 21st Century Medicine (CryoStor, HypoThermosol) BioLifeSolutions, Inc. (CryoStor CS10, HypoThermosol FRS) Teva Pharmaceuticals (Prograf, Copaxone) Veloxis Pharmaceuticals (Envarsus XR, Tacrolimus Extended Release) Sanofi (Thymoglobulin, Lemtrada) Astellas Pharma Inc. (Prograf, Advagraf) Roche (CellCept, Valcyte) Bristol-Myers Squibb (Nulojix, Orencia) Pfizer Inc. (Rapamune, Zithromax) Thermo Fisher Scientific (Gibco CTS, Dynabeads) Xenotherapeutics (Xeno-Kidney, Xeno-Skin) CryoLife, Inc. (BioGlue, On-X Heart Valve) Hansa Biopharma (Idefirix, HNSA-5487) OrganOx Ltd. (OrganOx metra, Liver Perfusion System) Transplantation Market Report Scope Report Attributes Details Market Size in 2023 US$ 13.76 billion Market Size by 2032 US$ 30.50 billion CAGR CAGR of 9.25% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segmentation Insights By Product, Tissue Products Segment Dominates the Transplantation Market The tissue products segment led the transplantation market with 60% market share in 2023 because of its extensive application in different surgeries, such as orthopedic, cardiovascular, and skin grafting procedures. These products are more easily accessible compared to organ transplants and can also be stored for longer durations, enhancing their use and reach. Advances in tissue engineering and sterilization technology have further spurred demand by allowing for safer, more effective uses. Moreover, increased incidents of trauma, burns, and sports injuries have significantly contributed to the increase in applications of tissue grafts, further strengthening this industry's dominance in the transplantation industry across the globe. By Application, Tissue Transplantation Segment Dominates the Market The tissue transplantation segment dominated the transplantation market with around 68% market share in 2023 because it is highly clinically applicable and demands a rise in interventions like bone grafting, skin grafting, and corneal transplantation. As compared to organ transplants, tissue transplants have less immunological resistance to overcome and reduced recovery times, making them widely accessible and practicable. Trauma cases, burns, orthopedic ailments, and degenerative disease are also causing their incidence to increase, and these further augment tissue transplantation demand. By End-Use, the Hospitals Segment Dominates the Market with approximately 49.35% Market Share In 2023 The dominance of the section is a direct result availability of sophisticated infrastructure, trained doctors, and efficient post-operative care necessary for a transplant to become a success. Hospitals generally have the resources, including multi-disciplinary teams and advanced surgical facilities[MD1] needed in complex organ and tissue transplants. Government and private financing for hospital-based transplant centers, as well as partnerships with organ procurement organizations, have also bolstered their dominance. The increasing number of transplant centers in hospitals and the increasing number of transplant procedures done in these facilities were major factors that helped the segment achieve its top market position. Buy a Single-User PDF of Transplantation Market Analysis & Outlook Report 2024-2032@ Transplantation Market Segmentation By Product Tissue Products Immunosuppressive Drugs Preservation Solution By Application Organ Transplantation Tissue Transplantation By End-Use Hospitals Transplant Centers Others North America Dominates the Transplantation Market, Asia Pacific Expected to Register Fastest Growth North America led the transplantation market with around 40% market share in 2023, with its sophisticated healthcare facilities, high concentration of top transplant centers, and high level of awareness of organ donation. The region has the advantage of a favorable regulatory environment and high public and private financing of transplant-related research. Moreover, the availability of trained healthcare workers and universal access to immunosuppressive therapies are factors that enhance transplant success, further strengthening North America's leadership role in the global transplantation market. Asia Pacific is expected to see the fastest growth in the transplantation market during the forecast period, led by increasing healthcare investments, growing medical tourism, and rising organ donation awareness. India, China, and South Korea are improving their healthcare infrastructure and implementing favorable government policies to combat organ failure. In addition, an increased incidence of chronic diseases like liver and kidney disease, and the increasing geriatric population, is driving the demand for transplant services in the region. Need Any Customization Research on Transplantation Market, Enquire Now@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Pricing Trends and Cost Analysis 5.2 Technology Adoption & Innovations 5.3 Regulatory & Compliance Statistics. 5.4 Consumer Awareness & Social Media Influence 6. Competitive Landscape 7. Transplantation Market by Product 8. Transplantation Market by Application 9. Transplantation Market by End-Use 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion Related Reports U.S. Organ Transplant Immunosuppressant Drugs Market to Reach USD 1.71 Billion in 2024, Growing at 4.64% CAGR Tissue Engineering Market Set to Surge from USD 16.8B in 2023 to USD 56.2B by 2032 Stem Cell Therapy Market Poised for Rapid Growth, Expected to Quadruple by 2032 Regenerative Medicine Market to Skyrocket from USD 32.5B to USD 236B by 2032, Driven by 24.66% CAGR About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
